caa a22 4500 469117184 CHVBK 20180323133128.0 cr unu---uuuuu 170328e19921001xx s 000 0 eng 10.1007/BF00177619 doi (NATIONALLICENCE)springer-10.1007/BF00177619 Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma [Elektronische Daten] [Maria Pons, Jonathan Finlay, Russell Walker, Diane Puccetti, Roger Packer, Mary McElwain] Twenty patients, aged 6 months to 20 years, with low-grade astrocytoma (LGA) participated in a chemotherapy trial of vincristine (VCR) and etoposide (VP-16). Fourteen children had recurrent progressive disease at entry on study. Prior treatment consisted of surgical resection alone (6), surgical resection and irradiation (4), surgical resection, irradiation and chemotherapy (2), surgery and chemotherapy (1), and irradiation and chemotherapy (1). Six patients were treated at initial diagnosis of LGA because they were less than 5 years old (5) or for a second primary tumor (1). Four recurrent patients and 3 newly diagnosed patients underwent surgical debulking of their tumors immediately prior to study entry. Tumors were located in the optic nerve/chiasm/hypothalamus (8), brain stem/cerebellum (4), cerebral hemispheres (3), midline structures (3), and spinal cord (2). The treatment plan administered in an out-patient setting consisted of weekly VCR 1.5 mg/m2 for 7 to 8 weeks and VP-16100 mg/m2 for 5 days repeated every 6 weeks for a total of 18 months of therapy. Responses were evaluated by computerized tomography or magnetic resonance imaging. Of the 20 patients, l exhibited a partial response maintained for 12+ months, 3 exhibited minor responses maintained for a period of 10+ to 35 months, and 11 maintained stable disease for 10 to 42 months. Of the 11 patients with stable disease, 2 were withdrawn early from the study without further therapy. Five of the 20 patients developed progressive disease; for 4 of these 5, this occurred during the first course of therapy. Subsequently, these 5 died due to tumor. Vincristine and etoposide produced minimal hematological and neurological toxicity and appeared to offer some benefit in patients with LGA. The authors suggest the therapy potentially can produce prolonged disease stabilization, or perhaps help avoid irradiation in the young child with LGA. Kluwer Academic Publishers, 1992 low-grade astrocytoma nationallicence chemotherapy nationallicence vincristine nationallicence etoposide nationallicence tumors nationallicence Pons Maria From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut Finlay Jonathan From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut Walker Russell From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut Puccetti Diane From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut Packer Roger From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut McElwain Mary From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut Journal of Neuro-Oncology Kluwer Academic Publishers 14/2(1992-10-01), 151-158 0167-594X 14:2<151 1992 14 11060 https://doi.org/10.1007/BF00177619 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177619 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Pons Maria From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut NATIONALLICENCE 700 1- Finlay Jonathan From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut NATIONALLICENCE 700 1- Walker Russell From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut NATIONALLICENCE 700 1- Puccetti Diane From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut NATIONALLICENCE 700 1- Packer Roger From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut NATIONALLICENCE 700 1- McElwain Mary From the Neuro-Oncology Program, The Departments of Neurology and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 14/2(1992-10-01), 151-158 0167-594X 14:2<151 1992 14 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer